Increased survival with enzalutamide in prostate cancer after chemotherapy
Scher, Howard I × Fizazi, Karim Saad, Fred Taplin, Mary-Ellen Sternberg, Cora N Miller, Kurt de Wit, Ronald Mulders, Peter Chi, Kim N Shore, Neal D Armstrong, Andrew J Flaig, Thomas W Fléchon, Aude Mainwaring, Paul Fleming, Mark Hainsworth, John D Hirmand, Mohammad Selby, Bryan Seely, Lynn de Bono, Johann S AFFIRM Investigators #
New England Journal of Medicine vol:367 issue:13 pages:1187-1197
Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy.